Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Fusfeld, Lauren ^a   Aggarwal, Jyoti ^a   Dougher, Carly ^a   Vera Llonch, Montserrat ^b   Bubb, Stephen ^b   Donepudi, Mrudula ^b   Goss, Thomas F ^a  

^a Boston Healthcare Associates Inc   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

Adherence; Compliance; Decision making; Drug therapy; Hepatitis C; Motivation; Treatment initiation

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; COMMUNITY; DEPRESSION; DISEASE DURATION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEALTH SURVEY; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MOTIVATION; RELAPSE; TELECONSULTATION; TREATMENT RESPONSE; UNITED STATES;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERVIEWS AS TOPIC; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MOTIVATION; TREATMENT OUTCOME; UNITED STATES;

EID: 84878008414     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-234     Document Type: Article

References (23)

1. Chack E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011, 31(8):1090-1101. 10.1111/j.1478-3231.2011.02494.x, 21745274.
2. Centers for Disease Control and Prevention Hepatitis C FAQs for the public 2009, [http://www.cdc.gov/hepatitis/c/cfaq.htm], Centers for Disease Control and Prevention.
3. Centers for Disease Control and Prevention Hepatitis C general fact sheet 2010, http://www.cdc.gov/hepatitis/HCV/PDFs/HepCGeneralFactSheet-BW.pdf, Centers for Disease Control and Prevention.
4. National Research Council Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C 2010, Washington, DC: The National Academies Press, National Research Council.
5. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54(4):1433-1444. 10.1002/hep.24641, 3229841, 21898493.
6. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49(4):1335-1374. 10.1002/hep.22759, 19330875.
7. Bacon BR, Mchutchison JG. Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. Am J Manag Care 2005, 11(Suppl 10):S296-S306.
8. Fraenkel L, Mcgraw S, Wongcharatrawee S, Garcia-tsao G. What do patients consider when making decisions about treatment for hepatitis C?. Am J Med 2005, 118(12):1387-1391. 10.1016/j.amjmed.2005.05.029, 16378783.
9. Strathdee SA, Latka M, Campbell J. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005, 40(Suppl 5):S304-S312. 2196220, 15768339.
10. Mcnally S, Temple-smith M, Sievert W, Pitts MK. Now, later or never? Challenges associated with hepatitis C treatment. Aust N Z J Public Health 2006, 30(5):422-427. 10.1111/j.1467-842X.2006.tb00457.x, 17073222.
11. Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time?. Dig Dis Sci 2007, 52(5):1168-1176. 10.1007/s10620-006-9579-1, 17357838.
12. Treloar C, Holt M. Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings. Aust Health Rev 2008, 32(3):570-576. 10.1071/AH080570, 18666886.
13. Grebely J, Genoway KA, Raffa JD. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008, 93(1-2):141-147.
14. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002, 35(3):704-708. 10.1053/jhep.2002.31311, 11870387.
15. Mchutchison JG, Manns M, Patel K. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123(4):1061-1069. 10.1053/gast.2002.35950, 12360468.
16. Lore V, Amorosa VK, Localio AR. Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis 2009, 48(2):186-193. 10.1086/595685, 2668718, 19086908.
17. Centers for Disease Control and Prevention Viral Hepatitis Surveillance - United States 2010, [http://www.cdc.gov/hepatitis/Statistics/2010Surveillance/index.htm], Centers for Disease Control and Prevention.
18. Jenner A, Scott A. Circulating beliefs, resilient metaphors and faith in biomedicine: hepatitis C patients and interferon combination therapy. Sociol Health Illn 2008, 30(2):197-216. 10.1111/j.1467-9566.2007.01061.x, 18290932.
19. Cotler SJ, Patil R, Mcnutt RA. Patients' values for health states associated with hepatitis C and physicians' estimates of those values. Am J Gastroenterol 2001, 96(9):2730-2736. 10.1111/j.1572-0241.2001.04132.x, 11569703.
20. Evon DM, Simpson K, Kixmiller S. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol 2011, 106(10):1777-1786. 10.1038/ajg.2011.219, 21769136.
21. Munoz-plaza CE, Strauss S, Astone-twerell J. Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. Int J Drug Policy 2008, 19(1):71-78. 10.1016/j.drugpo.2007.02.003, 2698452, 18312822.
22. Jessop AB, Cohen C, Burke MM, Conti M, Black M. Hepatitis support groups: meeting the information and support needs of hepatitis patients. Gastroenterol Nur 2004, 27(4):163-169.
23. Sylvestre DL, Zweben JE. Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy 2007, 18(5):406-410. 10.1016/j.drugpo.2007.01.010, 17854729.